The Board of Directors of TearLab Corporation increased the size of the Board from eight to nine members and appointed Joseph Jensen to the Board. Mr. Jensen, 43, has served as the President and Chief Operating Officer of TearLab Corporation since October 2013, and will become the Chief Executive Officer effective as of January 1, 2016. Mr. Jensen has over nineteen years of experience in pharmaceutical and medical device sectors spanning sales, sales management, marketing, and international positions.

From 1996 to 2013, Mr. Jensen served in managerial roles, most recently as the head of surgical marketing of Alcon Laboratories Inc., a division of Novartis.